BioSpace News Archive

RLS, Inc., the third-largest nuclear pharmacy network in the US, announced the appointment of Glenn Sullivan as Director of Regulatory Affairs.

Virpax® Pharmaceuticals, Inc. announced that Company CEO Anthony P. Mack has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs).

U.S. Oral Surgery Management – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – is announcing three additional partnerships with oral and maxillofacial surgery practices.

Omicsveu has achieved a milestone with its NanoVIP instrument – a slide-based automated staining system - fully automating the Opal manual staining protocol from Akoya Biosciences.

Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.

First Wave BioPharma, Inc. announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.15 per share, in exchange for new warrants as described below.

Centene Corporation announced it has completed the previously announced divestiture of Apixio, a leading artificial intelligence platform that enables value-based care, to New Mountain Capital.

McKesson Corporation announced the pricing terms of its previously announced offer to purchase for cash any and all of its outstanding 3.796% Notes due 2024.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in Prader-Willi syndrome (PWS).